Literature DB >> 1699491

Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses.

T W North1, R C Cronn, K M Remington, R T Tandberg.   

Abstract

The sensitivities of reverse transcriptases (RTs) from feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV) were directly compared. The two enzymes had similar sensitivities to three analogs of dTTP, namely, 3'-azido-3'-deoxythymidine 5'-triphosphate, 2',3'-dideoxythymidine 5'-triphosphate, and 2',3'-dideoxy-2',3'-didehydrothymidine 5'-triphosphate. Each of these analogs demonstrated competitive inhibition of both enzymes. Ki values for inhibition of FIV RT by these three inhibitors were 3.3, 6.7, and 1.8 nM, respectively; Ki values for inhibition of the HIV enzyme were 6.5, 5.9, and 8.3 nM, respectively. Ratios of the Ki for the inhibitor to the Km for the substrate were also determined for each inhibitor, and no differences between the two enzymes greater than threefold were observed. Inhibition constants for 3'-amino-3'-deoxythymidine 5'-triphosphate and 3'-fluoro-3'-deoxythymidine 5'-triphosphate were determined for FIV RT, and these were similar to published values for HIV RT. The activities of three dideoxynucleoside 5'-triphosphates against FIV RT were determined; ddGTP was slightly more potent than ddTTP, whereas both were much more effective than ddCTP. The activity of a noncompetitive inhibitor, phosphonoformate, was also examined with the FIV enzyme; it was much more active with poly(rA)-oligo(dT) as the template-primer than with poly(rC)-oligo(dG) or poly(rI)-oligo(dC).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699491      PMCID: PMC171861          DOI: 10.1128/AAC.34.8.1505

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases.

Authors:  Y Take; Y Inouye; S Nakamura; H S Allaudeen; A Kubo
Journal:  J Antibiot (Tokyo)       Date:  1989-01       Impact factor: 2.649

2.  Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases.

Authors:  R F Schinazi; B F Eriksson; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus.

Authors:  Y Hamamoto; H Nakashima; T Matsui; A Matsuda; T Ueda; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

Authors:  M Baba; R Pauwels; P Herdewijn; E De Clercq; J Desmyter; M Vandeputte
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

5.  Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome.

Authors:  T W North; G L North; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

6.  1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.

Authors:  M M Mansuri; J E Starrett; I Ghazzouli; M J Hitchcock; R Z Sterzycki; V Brankovan; T S Lin; E M August; W H Prusoff; J P Sommadossi
Journal:  J Med Chem       Date:  1989-02       Impact factor: 7.446

Review 7.  Animal models of AIDS.

Authors:  M B Gardner; P A Luciw
Journal:  FASEB J       Date:  1989-12       Impact factor: 5.191

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

10.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

View more
  16 in total

1.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Authors:  Y Q Zhu; K M Remington; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.

Authors:  H L Jordan; A S Pereira; M S Cohen; A D Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.

Authors:  J M Gobert; K M Remington; Y Q Zhu; T W North
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 6.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Authors:  K M Remington; B Chesebro; K Wehrly; N C Pedersen; T W North
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.

Authors:  K M Remington; Y Q Zhu; T R Phillips; T W North
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  RNase H activity associated with reverse transcriptase from feline immunodeficiency virus.

Authors:  R C Cronn; J D Whitmer; T W North
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.